Uptake of new treatment strategies for deep vein thrombosis: an international audit.

Détails

Ressource 1Télécharger: serval:BIB_05930D25F075.P001 (114.68 [Ko])
Etat: Public
Version: de l'auteur
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_05930D25F075
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Uptake of new treatment strategies for deep vein thrombosis: an international audit.
Périodique
International Journal for Quality in Health Care
Auteur(s)
Aujesky D.A., Cornuz J., Bosson J.L., Bounameaux H., Emmerich J., Hull R.D., Mackay E., Perrier A., Quan H., Tsuyuki R.T., Ghali W.A.
ISSN
1353-4505
Statut éditorial
Publié
Date de publication
2004
Peer-reviewed
Oui
Volume
16
Numéro
3
Pages
193-200
Langue
anglais
Résumé
OBJECTIVE: Study of the uptake of new medical technologies provides useful information on the transfer of published evidence into usual practice. We conducted an audit of selected hospitals in three countries (Canada, France, and Switzerland) to identify clinical predictors of low-molecular-weight (LMW) heparin use and outpatient treatment, and to compare the pace of uptake of these new therapeutic approaches across hospitals. DESIGN: Historical review of medical records. SETTING AND PARTICIPANTS: We reviewed the medical records of 3043 patients diagnosed with deep vein thrombosis (DVT) in five Canadian, two French, and two Swiss teaching hospitals from 1994 to 1998. Measures. We explored independent clinical variables associated with LMW heparin use and outpatient treatment, and determined crude and adjusted rates of LMW heparin use and outpatient treatment across hospitals. RESULTS: For the years studied, the overall rates of LMW heparin use and outpatient treatment in the study sample were 34.1 and 15.8%, respectively, with higher rates of use in later years. Many comorbidities were negatively associated with outpatient treatment, and risk-adjusted rates of use of these new approaches varied significantly across hospitals. CONCLUSION: There has been a relatively rapid uptake of LMW heparins and outpatient treatment for DVT in their early years of availability, but the pace of uptake has varied considerably across hospitals and countries.
Mots-clé
Aged, Ambulatory Care, Anticoagulants/therapeutic use, Canada, Female, France, Health Services Research, Heparin, Low-Molecular-Weight/therapeutic use, Humans, Male, Medical Audit, Middle Aged, Patient Care, Switzerland, Venous Thrombosis/drug therapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
05/03/2008 15:56
Dernière modification de la notice
25/09/2019 6:08
Données d'usage